The exogenous administration of basic fibroblast growth factor to regenerating skeletal muscle in mice does not enhance the process of regeneration.
The effects, in vivo, of the exogenous administration of bFGF on myogenesis of regenerating skeletal muscle was assessed either morphometrically or autoradiographically in three separate models of muscle injury in mice: crush-injured, denervated, and dystrophic (mdx) muscles. The bFGF was administered at various doses and different time schedules, sometimes in combination with heparin, into injured tibialis anterior muscles of mice. Delivery of the bFGF was either by direct intramuscular injection or by the sustained release from 888polymers (Hydron or Elvax) implanted into the muscles. The bioactivity of bFGF was confirmed in vitro by measuring its ability to stimulate the proliferation of BALB/c-3T3 fibroblasts and muscle precursor cell lines. The ability of bFGF to stimulate angiogenesis in vivo was confirmed by the implantation of controlled-release polymers containing bFGF into the normally avascular cornea of rats. No measurable effect of bFGF was seen in any of the models of skeletal muscle injury under these experimental conditions, indicating that the availability of biologically active bFGF is not a limiting factor in the regeneration of skeletal muscle following injury.
Mitchell
C A
CA
Department of Pathology, University of Western Australia, Nedlands, Australia. CMitchell@alpha.kerckhoff.mpg.de
McGeachie
J K
JK
Grounds
M D
MD
D000818:Animals; D002455:Cell Division / Q000187:drug effects; D002467:Cell Nucleus / Q000378:metabolism; D002478:Cells, Cultured; D003315:Cornea / Q000187:drug effects; D003714:Denervation; D004337:Drug Carriers / Q000737:chemistry / Q000378:metabolism; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage / Q000032:analysis / Q000494:pharmacology*; D006493:Heparin / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D018101:Mice, Inbred mdx; D018482:Muscle, Skeletal / Q000166:cytology / Q000187:drug effects* / Q000293:injuries* / Q000378:metabolism; D009136:Muscular Dystrophies / Q000235:genetics; D011145:Polyvinyls / Q000378:metabolism; D051381:Rats; D012038:Regeneration / Q000187:drug effects*; D013392:Sucralfate / Q000378:metabolism
D004337:Drug Carriers; D011145:Polyvinyls; D016222:Fibroblast Growth Factor 2; C016438:ethylenevinylacetate copolymer; D013392:Sucralfate; D006493:Heparin